Ogdie A, et al. - In this investigation, researchers analyzed predictors of remission among psoriatic arthritis (PsA) patients initiating an inhibitor of tumor necrosis factor (TNF). Patients with PsA registered in the Corrona Registry between 2005 and 2013 were followed up from the initiation of a TNFi inhibitor (TNFi; etanercept, adalimumab, infliximab, certolizumab, or golimumab) to the nearest 12-month visit. Additional criteria for inclusion included 3 tender or 3 swollen joints. According to results, 14% of the remission and 37% of the LDA (or remission) were achieved. Achieving remission was negatively associated with female sex, obese body mass index, hypertension, previous biologic use, and baseline pain but positively associated with a college education. Findings revealed that few PsA patients achieved remission by Clinical Disease Activity Index criteria in a US-based registry. The achievement of remission on a TNFi is influenced by female sex, obesity, comorbidities and education.